Chapter

The role of bisphosphonates in the systemic treatment of prostate cancer

Alan Horwich and David P Dearnaley

in Systemic Treatment of Prostate Cancer

Published on behalf of Oxford University Press

ISBN: 9780199561421
Published online May 2011 | e-ISBN: 9780199607372 | DOI: http://dx.doi.org/10.1093/med/9780199561421.003.0008

Series: Oxford Oncology Library

The role of bisphosphonates in the systemic treatment of prostate cancer

Show Summary Details

Preview

• Bone metastases are a major cause of morbidity in metastatic prostate cancer • Bisphosphonates have shown evidence of activity in inhibiting osteoclasts and in reducing the incidence of skeletal-related events in patients with bone metastases • Bisphosphonates may aid pain control in some patients with castrate resistant symptomatic bone metastases • Bisphosphonates moderate and reverse bone density loss associated with androgen suppression • There are significant side effect risks from long-term use of potent intravenous bisphosphonates including osteonecrosis of the jaw • The use of bisphosphonates should be considered in patients with prostate cancer at high risk of a skeletal related event • Ongoing clinical trials will further define the role of bisphosphonates in prostate cancer.

Chapter.  1737 words. 

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.